Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1000341-51-4 | MDL No. : | MFCD09263244 |
Formula : | C7H5BrN2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | KJTANNMEOBCHKP-UHFFFAOYSA-N |
M.W : | 197.03 | Pubchem ID : | 24729356 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 43.79 |
TPSA : | 28.68 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.02 cm/s |
Log Po/w (iLOGP) : | 1.57 |
Log Po/w (XLOGP3) : | 2.09 |
Log Po/w (WLOGP) : | 2.33 |
Log Po/w (MLOGP) : | 1.34 |
Log Po/w (SILICOS-IT) : | 2.75 |
Consensus Log Po/w : | 2.02 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.04 |
Solubility : | 0.178 mg/ml ; 0.000903 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.32 |
Solubility : | 0.938 mg/ml ; 0.00476 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.77 |
Solubility : | 0.0337 mg/ml ; 0.000171 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.83 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338-P310 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
56% | With acetic acid at 120℃; for 6h; | 35.1 Preparation of 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridine-3-carbaldehyde (Example Compound 35) To a mixture of 46 (300 mg, 1.5 mmol) and hexamethylenetetramine (0.32 g, 2.25 mmol) was added AcOH (2 mL). The reaction mixture was stirred at 120 °C for 6 h and was quenched with H?0 (5 ml). The precipitate was collected by filtration to afford 65 (190 mg, 56%) as a yellow solid:3H NMR (300 MHz, DMSO-d6) δ 32.4 (s, 1H), 10.1 (s, 1H), 8.58 (d, J = 2.1 Hz, 1H), 8.47 (s, 1H), 8.18 {d, J = 2.1 Hz, 1H). |
[ 1265139-77-2 ]
Bis((6-bromopyridin-2-yl)methyl)amine
Similarity: 0.83
[ 126325-47-1 ]
6-Bromo-2-methylpyridin-3-amine
Similarity: 0.81
[ 1219022-46-4 ]
6-Bromo-1,2,3,4-tetrahydro-1,5-naphthyridine
Similarity: 0.81
[ 1215387-58-8 ]
5-Bromo-1H-pyrrolo[2,3-c]pyridine
Similarity: 0.78
[ 1190319-51-7 ]
6-Bromo-2-methyl-1H-pyrrolo[3,2-b]pyridine
Similarity: 0.76
[ 73177-35-2 ]
2-Methyl-1H-pyrrolo[3,2-b]pyridine
Similarity: 0.83
[ 1219022-46-4 ]
6-Bromo-1,2,3,4-tetrahydro-1,5-naphthyridine
Similarity: 0.81
[ 1215387-58-8 ]
5-Bromo-1H-pyrrolo[2,3-c]pyridine
Similarity: 0.78
[ 944937-53-5 ]
6-Bromo-1H-pyrrolo[3,2-b]pyridine
Similarity: 0.76
[ 1190319-51-7 ]
6-Bromo-2-methyl-1H-pyrrolo[3,2-b]pyridine
Similarity: 0.76